Drug intelligence / Profile preview

5-fluoro-1-[4-(4-phenyl-3,6-dihydropyridin-1(2h)-yl)butyl]quinazoline-2,4(1h,3h)-dione

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is an experimental small molecule with the chemical formula C23H24FN3O2 and a molecular weight of approximately 393.46 g/mol[1][3]. It is a quinazolinone derivative featuring a fluorine atom at position five and a butyl-linked phenyl dihydropyridine moiety. The compound has been referenced in chemical databases as FRQ and PD005033[7]. There are no approved medical indications or clinical trials associated with this drug as of now[4]. Mechanistically, it has been identified in structural studies as binding to poly [ADP-ribose] polymerase enzymes (PARP), specifically PARP1 and PARP2[3], suggesting potential activity as a PARP inhibitor.

Other names
5-fluoro-1-[4-(4-phenyl,3,6-dihydropyridin-1(2H)-YL)butyl]quinazoline-2,4(1H,3H)-dione5-fluoro-1-[4-(4-phényl,-3,6-dihydro,-1(2H)-pyridinyl)butyl]-2,4(1H,3H)-quinazolinedione5-fluor-1-[4-(4-pheny,l3,6-dihydro,-2H-pyridin,-1-y,l)buty,l]-3,H-quina,zoline-,2,,4-di,on,equinazolidinone analogue 2b
02

Targets

PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on 5-fluoro-1-[4-(4-phenyl-3,6-dihydropyridin-1(2h)-yl)butyl]quinazoline-2,4(1h,3h)-dione.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluoro-1-[4-(4-phenyl-3,6-dihydropyridin-1(2h)-yl)butyl]quinazoline-2,4(1h,3h)-dione.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call